Safety and Efficacy of SBI-087, a Subcutaneous Agent for B Cell Depletion, in Patients with Active Rheumatoid Arthritis: Results from a Phase II Randomized, Double-blind, Placebo-controlled Study

REFERENCES

1. 1.↵
   1. Conti F,
   2. Ceccarelli F,
   3. Massaro L,
   4. Cipriano E,
   5. Di Franco M,
   6. Alessandri C,
   7. et al.

   Biological therapies in rheumatic diseases. Clin Ter 2013;164:e413–28.

   OpenUrlPubMed
2. 2.↵
   1. Burmester GR,
   2. Feist E,
   3. Dorner T

   . Emerging cell and cytokine targets in rheumatoid arthritis. Nat Rev Rheumatol 2014;10:77–88.

   OpenUrlPubMed
3. 3.↵
   1. Nakken B,
   2. Munthe LA,
   3. Konttinen YT,
   4. Sandberg AK,
   5. Szekanecz Z,
   6. Alex P,
   7. et al.

   B-cells and their targeting in rheumatoid arthritis — current concepts and future perspectives. Autoimmun Rev 2011;11:28–34.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Kaur K,
   2. Kalra S,
   3. Kaushal S

   . Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis. Clin Ther 2014;36:1074–86.

   OpenUrl
5. 5.↵
   1. Buch MH,
   2. Emery P

   . New therapies in the management of rheumatoid arthritis. Curr Opin Rheumatol 2011;23:245–51.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Campbell J,
   2. Lowe D,
   3. Sleeman MA

   . Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis. Br J Pharmacol 2011;162:1470–84.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Edwards JC,
   2. Cambridge G

   . Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 2001;40:205–11.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Faurschou M,
   2. Jayne DR

   . Anti-B cell antibody therapies for inflammatory rheumatic diseases. Annu Rev Med 2014;65:263–78.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Scher JU

   . B-cell therapies for rheumatoid arthritis. Bull NYU Hosp Jt Dis 2012;70:200–3.

   OpenUrlPubMed
10. 10.↵
    1. Brulhart L,
    2. Ciurea A,
    3. Finckh A,
    4. Notter A,
    5. Waldburger JM,
    6. Kyburz D,
    7. et al.

    Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study. Ann Rheum Dis 2006;65:1255–7.

    OpenUrlFREE Full Text
11. 11.↵
    1. Higashida J,
    2. Wun T,
    3. Schmidt S,
    4. Naguwa SM,
    5. Tuscano JM

    . Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. J Rheumatol 2005;32:2109–15.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    Genentech Inc. Rituxan (rituximab): Full prescribing information, 2010. [Internet. Accessed August 29, 2016.] Available from: www.gene.com/download/pdf/rituxan_prescribing.pdf
13. 13.↵
    1. Jin L,
    2. Cambier JC

    . SMIP-016 in action: CD37 as a death receptor. Cancer Cell 2012;21:597–8.

    OpenUrlPubMed
14. 14.↵
    1. Dunussi-Joannopoulos K,
    2. Tchlstlakova L,
    3. Oliand S,
    4. Zollner R,
    5. Brady WA,
    6. Mohler KM,
    7. et al.

    Kinetics of B cell depletion and reconstitution in peripheral blood and lymphoid tissues after a single dose of SBI-087, a humanized anti-CD20 SMIMTM, in cynomolgus monkeys. Ann Rheum Dis 2008;67 Suppl II:190.

    OpenUrl
15. 15.↵
    1. Cohen S,
    2. Clowse M,
    3. Pardo P,
    4. Bhattacharya I,
    5. Menon S,
    6. Gourley I,
    7. et al.

    Safety, tolerability, pharmacokinetic and pharmacodynamic properties of SBI-087, a CD20-directed B-cell depleting agent: Phase 1 dose escalating studies in patients with either mild rheumatoid arthritis or systemic lupus. Clin Ther 2016;38:1417–34.

    OpenUrl
16. 16.↵
    1. Arnett FC,
    2. Edworthy SM,
    3. Bloch DA,
    4. McShane DJ,
    5. Fries JF,
    6. Cooper NS,
    7. et al.

    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Felson DT,
    2. Anderson JJ,
    3. Boers M,
    4. Bombardier C,
    5. Furst D,
    6. Goldsmith C,
    7. et al.

    American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.

    OpenUrlCrossRefPubMed